UTHR

United Therapeutics Corporation (UTHR)
Healthcare • Drug Manufacturers - Specialty & Generic • $487.61 • MCap: 20,913,930,240 🌐
https://www.unither.com • United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
Buy Decision Core
Total Score
60
Business Quality
25
Financial Strength
14
Growth Outlook
5
Momentum
3
Price Action
Current
487.61
52W High
596.76
52W Low
394.62
Above 50DMA
525.68 (-7.24%)
Above 200DMA
523.45 (-6.85%)
Relative Strength
Relative Strength
0.0
RS 3M
-0.11
RS 6M
0.02
RS 9M
0.01
RS 12M
0.21
Fundamentals
Revenue Growth
-0.02%
Earnings Growth
0.13%
ROE
0.19%
ROA
0.12%
Valuation
PE (Fwd)
16.24
PEG
2.22
P/B
3.25
Upside
36.24%
Risk
Beta
0.56
Short %
0.06
Risk Score
3.00
Analyst
Rating
buy
Target
664.33
Beta
0.56
Analysts
0


Total Score
60
Upside
36.24%
Relative Strength
0.0
Beta
0.56
Why Buy?
  • Analyst upside exceeds 15%
Key Risks
  • Revenue growth is negative
Score Breakdown
Business
25
Financial
14
Growth
5
Valuation
5
Risk
3
Momentum
3
Technical
52W High: 596.76
52W Low: 394.62
Above 50DMA: -7.24%
Above 200DMA: -6.85%
Valuation
Forward PE: 16.24
PEG: 2.22
P/B: 3.25
Upside: 36.24%
Risk
Beta: 0.56
Short Float: 0.06%
ROE: 0.19%
ROA: 0.12%